Stemcyte International Ltd. · TWSE:4178
Stemcyte International — Investor Presentation (April 2026)
54 slides from Stemcyte International's investor presentation, April 2026
Slide 1: StemCyte International, Ltd. pre-listing investor conference
mk E-KY WY StemCyte|4178 EmaVaARHAS KERB AARAA (StemCyte International, Ltd.) jw@
Slide 2: Disclaimer
@ StemCyte RGR ZARA SER ZA: GRSBRE - MESAA : 4SCOSRASARAIEN Bl Ae Sha SE SAS SS RI AAS 2a: RAR R AEE - AATAR AE URES 2 SRR VMERRARBAAR : DRAW MAM=ES > ZARA AERA S@AR : GAA harek - AGRE - mR SEMRACASMAARRZ ME URAHARA MASE ZARSAR - ARP MEK ZAM ARBAAS A BA AILARARAA IA + WABASH AYA RABE RAH - HBOS HRSA
Slide 3: StemCyte Mission Statement
kE-KY 4178 @ StemCyte Fa CS IE StemCyte Mission Statement At StemCyte, we are dedicated to helping the world's physicians save more lives by providing high quality, safe and effective stem cell transplantation and therapy to all patients in need. That’s not just saving cord blood, it is above “Savin
Slide 4: @ alii — Boxee!
@ alii — Boxee! 2 @ Wik — SERRA 1A / Dial Ae @ €2R —- ABER MihiaRaAadMSABFDA kE-KY @ StemCyte 7 Dub Fale @ SS — SPRBI RAs io Ree es A A a ea ee Bis lit Aaa a SEP See IT PE ete CL
Slide 5: Contents
7 1. Aaa A al @ StemCyte k#-KY 4178 © AGT @ BREE © AA ee MSEK @ BITARR © BSA © Eki © META 2538 pf eS 3. KRE yeye © SEA © SEK) e Sez FRAG @ AAA @ AMABEKE @ ANKBARIS © = ° Arima 4. 2K AB 3 © ABR ERHEALE 5. faa PRS
Slide 6: Company overview
kE-KY 4178 @ StemCyte * 2a + Soh tz - Age 4» ol set IR - g2Bw Ly 4 > RITA - 28 + ESKER + RTT AB
Slide 7: Company profile
= se“ 43a) FAT] Ant BUBAR aziz AHA FPSB it ALTAR = AE RT kE-KY 4178 @ StemCyte termes FS5 SABRE 1,936,370F70 ( #1B : 1,738,821 77 ) FB KE RIIA1997 » KEEFER 2013 6A 268 FECGMPRR ; GSM GTP RR AM S4A (RPHEBESIA - Bt) Big 63A (HR PRBARI4A - 3+ + 11f fat ) Gat 117A AA ED it Se OT Se ATH BE AE AE Ae A HAR
Slide 8: Company history and milestones
re RE TE 8M RAS eR i tis B (AABB) ia cxth| Accredited StemCyte, Inc. K+ MIT emaKc Ajslt— SAERER RexeMNN SBT ES aig lt— Se 0 SF A BB i RE x PRIA AAT (Cell) ~ = PIRBR REGENECYTE® BY 4S FDA RS Mn or 258 (BLA) 4H 878 RZ SS) PT ee oe) StemCyte| k#-KY 4178 PRBR QB MGS RR IRE Emma Py rey. _ Baas. ie tas SD
Slide 9: Milestones: cord blood transplant and clinical achievements
kE-KY 4178 @ StemCyte 2023 ee det [If — fi BCRSSRBALANSMT «Cell) REGENECYTE?® s@/a 2 ia con cones IE (8 FA 2k ECCROS AR SEA Fs I A Ba + BS SBS ae MS ta eA ae tS Ba tt 2 (AML) 40 es Sy ney Tt 2 HIV-1 remission and possible cure in a woman after haplo-cord blood transplant (Be Re Ee 22 7s i PAR it 8 a
Slide 10: Post-COVID trial published in eClinicalMedicine
2026 “~ 7 ABR Te EPR HAR FURL AS SERIE i PRAT The Lancet Fil « eClinicalMedicine » ney kE-KY J StemCyte|4178 pi REGENECYTE® arices REGENECYTE cord blood cell therapy in post-COVID syndrome: iS a phase Ila randomized, placebo-controlled trial = Yen-Wen Huang,“ Ying-Chieh Chen,°“ Ernest Yin Lun Lau,“*
Slide 11: Group structure and facilities
kE-KY 4178 @ StemCyte s ESRB AAR AS 4 ARAB AML - te rte Int ti |, Ltd. — ATURE : Cayman Islands 100% AMAT AE - BW : 2013 ARZBalaA [100% 100% ] 100% RREERAARAG AB XzMMBOBIRAS StemCyte, Inc. (US) SILI BA : Bait BRIA : QS eIb BRUIHWEA : Delaware BUTE : 2016 SLE : 2000 BOLE : 1997 100% RT AE B e/RisR SA
Slide 12: Management team
k#-KY J StemCyte|4178 A EB aa Jonas Wang, Ph.D. Chairman #23 FS Tong-Young Lee, Ph.D. CEO #849 SERRATE ¢ &€ Johnson & Johnson Asi AaB - GAREBSEt KREBS ° SR1ORL bRbARA Bis 30 Ll FSA © Be MBE ZLDr. Judah Folkman = EBIB30 FF Be TH SS Se SB SR SS A . Sieeevaaiin / Lucentis / Elyea (4 #58815 0 70) S Bs H
Slide 13: Major shareholders
AY +A BRR AS BR SAB (2026438308) SG FRIAR ARRAG $2 — Shik BR ARRAS) BERR AARA a SPH alRRARAARAA ta Seis he 1 APR oO] Bi St ie AR fh ABRA l AKER HRI Re ARRAS) RTE mS PRE MAR AR APRA) a it A Bi 23,192,150 15,000,000 13,900,000 13,805,424 13,269,000 9,383,615 5,658,674 4,111,073 4,000,000 3,252,532 105
Slide 14: Board and investors
= kts FCB : RE CHINN OAIRA Sl it Re PRCA : IE EEO IRA) mem FIRAORA : MEAG BAIA + SS CENVASMRRA Set + Sycamore Ventures& BH Johnson & Johnson Consumer Products# 5k i 38 2B ll #8 Bt FS MAR (QR) BES MOLAR (MANA ERE ERAS BARAT R BRE (MAA AHA ma BReadingA AB Pras > (2 2292 {7 2 1A (MSc ISIB) HUBAASM BSS
Slide 15: Management and R&D team
E == 4=| ges vex, . Bvetelena aS BRAS) TRA : MBS {3h BE Sues k#-KY J StemCyte|4178 ESR + AANA KAD RE BRL + BURA RIL A (A) ASR AAS + PR se T RIL IS + BARGER + SSPERS SSR + SStRERRRAESSS / RHP BRAS SUBSE £285 + PHI] ihe + ik bem eae + BIAS Sale SR | BES MS SBSR WARRBERA ‘ BBARLVAN SS eBSR | ReRENESSBS
Slide 16: Awards and recognition
k#-KY 4178 @ StemCyte 1S RIKER - 2025 Taiwan BIO Awards tix eit "FESR MR. - ; Wag one 7 2 sna ’ i 2025-07-22 Sit Rinse 2025-09-23 Fa AB Ait Hz Fe MS HN ak sf
Slide 17: Cord blood bank and GTP facility
N= 9917 Ik#E-KY = @ StemCyte|4178 ia loa 7 1 Aa ae ees 15014 > **O GTPRR gm s50be a _— . ' Sch orp (in) <— HAS ts IF, 3504 \ 32 0] COMP ~1,3005F | i Gis 63.A; ta, ts Sb 22% FH 54A; RBABE zl
Slide 18: Business overview
Ihe re St 7a > Al Bed at > An hel He He > ARG ARIS BELA @ StemCyte kE-KY 4178
Slide 19: Financial results
kE-KY . = @ StemCyte|4178 Ara BU: wa8+70 202348 20244 E 2025+ E SUA 362,777 382,687 368,914 = Al 105,690 117,982 126,821 Sil Abas (331,593) (204,915) (173,144) = eaRES MA (92,700) (140,988) (52,426) fe tb(%) 58.56 42.12 43.73 mn) Cb 38 (%) 679.40 1,111.33 1,042.24 FE US We ak We #S 3 (%) 3.53 3.24 2
Slide 20: Cord blood bank and API/CDMO business
9 StemCyte| axe — SikmA MAABOE mi oe ARE RAS AAR IS API/CDMO Ms > 36,0008 SIE HUES REP aS (US FDA: & an 8 an S38 Si/ TFDA:8 A el BE FR See ; SERB ERG! >2,3008) ; SRSA > 35088 ae BS rs (10 A A es US FDA » TFDA » AABB « FACT * WMDA nae) SIE S/ AABB:3S EH MRR A RR HE B/ FACT: AM RO Rata BS B@/ WMDA AS
Slide 21: Cord blood bank inventory and accreditations
kE-KY J StemCyte|4178 f= oo fe sen) — Sisitt— Bisglk— SRRA LACAN >36,000 #& (aaH me) AMR MARBLE = 95% aA EES = 205 Ree (SASF te) MRFH > 36,0008; SRB >2,3006) ; ABABA >3508 SiS It — 3838 3 RR on a MD ABB US FDA + TFDA + AABB « FACT ‘ WMDA (US FDA:ERIR BHR SIE HOA BA BRS AABB: RMN yA MEME / FACTOR SRR
Slide 22: Business model and revenue streams
kE-KY ST ET EA @ StemCyte| 4178 = 2 FZ IL fie ae Mie GER ta #1/# #208 #208 #1/# Ske MA mm BRUM SERRE Sawa mie eter mes er ey BD Biepeem Hh Be RIE Ratt GED bIE $BSSHOR ith ia (tng a oH ree ee Pret tent eee a ERB tse HARB ES Baca BaeHnER SUERAMES MM BA S-eS BRA HBSS Sa Se BS 2 (E04 BE NI SES EGE IEEY
Slide 23: US FDA BLA approval
=IE—FDA BLAM ha ff Hel #2 REGENECYTE® wt ay =k a =o re kwa st~ ADMINISTRATION, g [ery U.S. FOOD & DRUG Our STN: BL 125764/0 BLA APPROVAL November 20, 2024 StemCyte, Inc. ores” (b) (4) Dear Dr. (6) (4) Please refer to your Biologics License Application (BLA) received January 7, 2022, submitted under
Slide 24: REGENECYTE and CDMO API business
SEK ot dl LHS) Yen Ve = kE-KY % StemCyte US FDA REGENECYTE® #2 Me A th aR Hel WAS TE Feel 35 je th ke CDMO API #4 Fé tk TAZE fe ARIS TH _.f
Slide 25: Business strategy
AM Bel = a0 kE-KY @ StemCyte|4178 An Pied sat 2 lH Bed 43 Hs FRRALS ABT Ml Ais FDA #240 #9t8 An el Fai 282 OH 3S BS ae EK ANAS EH @US FDA #8 (BLA) BMAME @ HERCDMO/CRO KE @US FDA [HABE P Rare Eee ORME @US/TW FDA — Sabi PR ae EGR 0 EAP CREME All Hed HR 335 SEK GRAS ARES fal A (bia 22 A BER © ARG te ©
Slide 26: REGENECYTE pipeline
BER k#-KY Ath Ae Ft 2 Pipeline REGENECYTE® MAMA > SOTEI Mit SRM i+ a @ StemCyte|4178 2024 ©2025 «= 2026 «= 2027 «= 2028 = 2029-=S «20302031 awasen TER, [aM BLAIR ee Bi /B 4/38 B/S BLA in tte Phase II Phase II {#4 S58 26 |
Slide 27: REGENECYTE FDA approval
20 ed t # REGENECYTE® ema At PRIA 1B BA) ABR Bh BE RIS 79(8=7c A FDA #& A 3 2 yes tae 4 Alo Bed art BH ZS] (g [en U.S. FOOD & DRUG ADMINISTRATION Our STN: BL 125764/0 StemCyte, Inc. Attention: (b) (4) (b) (4) Dear Dr. (B)(4) BLA APPROVAL November 20, 2024 Please refer to your Biologics License Appli
Slide 28: REGENECYTE efficacy and safety data
20 ed er @ REGENECY TE ® csmaazenam ARIRAM RUE RES fe ABR LALCE BSS 0 #6 An a YS DB ed SB (BMS ) (22ENARMBEA SY) 100% 30 = e 3S $ 8s 2 8 (Day) (Day) Neutrophil Recovery at Day 42 (%) ~ eC) 2 Platelet Recovery at Day 100 (%) Median Time to Neutrophil Recovery Median Time to Platelet Recovery Ml REGEN
Slide 29: REGENECYTE market opportunity
2iH Ae ah 282 REGENECYTE® cansameceinse) 1 l ABR Bh BE a ae a bi US FDA zc tie (RAR ie 70 A He Me AE REGENECYTE® > (J StemCyte RegeneCyte® CGR A FDA EEE S78 (BLA) EF CIEE (STN - 125764) TRO BARR) VPS is (T1431 BS A SS DRS BS Ea RIS IM Aah Clear View Market Insights 2025; Towards Health Care 2025; Pr
Slide 30: Post-COVID and chronic fatigue indications
“BWA Sn BE REGENECYTE® esaumy nae ae a Ail] |= BFDAN Rad rhs ae kK 34 IR om el oe MR] Post-Covid Conditions Ee rg Te (BE (PCC) 1B tt BRS ire (BF (CFS) RE TR ALAR ZI rt VA HIE BBE pals) i SSR IF REBRRR BE Be AUR SB Arne FA RTs TE RET) A Reins he 328(a It os ese ae) 1495837 |
Slide 31: Post-COVID Phase IIa trial results
ABST BE REGENECYTE® cawzem) 2IRS OID M0 MIO AM ae = REGENECYTE cord blood cell therapy in post-COVID syndrome: | ERM aia ie a phase Ila randomized, placebo-controlled trial = oF ‘Yen-Wen Huang ** Ying-Chie * Emest Yin Lun Lau* Yu-Chin Su, Lung-Kvo Tai” ithal,"* Jonas Wang” ani + AMPH AD RAE BES (TEA
Slide 32: Competitor comparison in post-COVID
Ran ae RED M- ABR Bh BE Bll 2 Fe oe PRAY A A ee = REGENECYTE® : Ampligen® =m (HPC, Cord Blood) Paxlovid (AMP-518 - Rintatolimod) UN StemCyte, Inc. 18 322K Pfizer AIM ImmunoTech, Inc. Emaw AAS AS \\F KF RARER! RTA ct oe Ms BNERRSFR © (BL 125764) _ eee humrons Sore an re ne te Bt BARR fim ae SA (GALE)
Slide 33: FDA designations and expanded access
437 HE REGENECYTE® caxeem —— A/G FDANE Ma SE RSS Mee mee oe mies AE Our yee: INE RMATa Bi He a Regenerative Medicine Advanced Therapy RMAT2252 oe use sees PRR ERE kthrough _— ( RRBs Fast Track / RARE Breakthrough ) > Oy MR BED FA aS TE (SBR Cau] / (—38) / ( —FRb) ) ff ES PID = Bia HG ool BR (Expande
Slide 34: Clinical development timeline
ABR Bh BE Ah RE aT 2 REGENECYTE® caaiaiaz oF SGRER RM ARs FDA HES Fire DEERE (6Y) Ga 2Y s- # (10~15Y) BD ti Bx ail Piiasey) (pts) Phase !1a(20pts) Phase IIb (60pts) Phase III (120pts) 203Y 2~3Y¥ 3~4Y 3.4Y Phase III (60pts) ARS HA 3Y 1Y ABSA Fe HE el SS UC SS BS SS FS 6~ 10 | TARSAL) BR Sz t38 3,000
Slide 35: Long COVID market
4if Ae ah 282 REGENECYTE® (asia ClearView Market Insights 2025 ean SKB 281 SICH se openPR 5 Worldwide Public Relations @ Categories Submit Press Release Ord Global Long COVID Market to Grow Tenfold by 2031 as Medical Understanding and Therapeutic Options Advance 05-03-2025 1226 PM CEr | Advertsing,
Slide 36: Anti-aging market
AAT REGENECYTE® (asiaam 1 AR Bh BE RADA SNR 1,495 HTC! =k Pomc eee | 20254F rece c ecco eee eee | 20344 1495fa70 Precedence Research 2026 Es ee 78017 | | Precedence Anti-aging Market Size 2025 to 2035 (USD Billion) pee eee. - RESEARCH wee eee eee - 160 cee eee ‘ 140 $140.11 $131.27 en $123.00 20 a $
Slide 37: Stroke clinical data
ARN RRBE REGENECYTE® cetomnmy ARRAAORAEPRRSMIA RIERS OR Stk PAAR IS ROX 549] FS BAS PG BCP BLAS BL(NIHSS) ansvanepiee-pa) H asi SAG (Bl BAS AEH HE EAE (BI) Sy SE BE a a retemesscevy FE] Dayne BENET RAN AIAG VV V WV 0 i) sf = REGENECYTE® < Fer Sorio SF Soe } 8 a 3 ‘hange from baseli (NIHSS) oN ON 6,
Slide 38: Stroke therapy comparison
1 1 iw = 4 el Fh a8 aE he ch S a BACB eS SHREW eee ® ae reeci coud Actilyse MultiStem UMSCO1 UMC119-06 LT3001 “ Blood) (t-PA) (ROSSMAN) (RRASSSME) (RM) = DFR) PRIME StemCyie, Inc, | Boehringer Athersys at SiR AA IG BRR Ingelheim enh ainam KER MAAS AAR MER INA FR en RI Bb R= RHA RB ROH ee Re Ce is _
Slide 39: Stroke market
2if AG ah 282 REGENECYTE® ateeaag eee -4 i | 20248 380f8 250 eee eee -4 203455 7628 RIC | : CAGR Towards Health Care 2025 1 l AR Bh BE Slt lS 762 FIL mR Stroke Diagnostics and Therapeutics Market Leveraging Al, Wearable Technology & Point-of-Care Testing The stroke diagnostics and therapeutics marke
Slide 40: REGENECYTE market potential
if Red FT #2 REGENECYTE® ABR Bh BE anewee Rey 7 Osx 1,495 6 > BRVSSHFDARE 7? > 7 ® > Fe zE al Bee ti (EC REGENECYTE Rens he 328 825 rat HEP Mil rf 3a 162625 |
Slide 41: Patent portfolio
SF fi I ABR Bh BE 5 Fil ti se wz iam - RARGSES 208A TX) RS © A Ge ® fa aha | | | | yer Dy 62/889,225 18/627,750 61/072,173 61/444,207 62/848,230 (2005/11/3) (2005/6/2) (2019/8/20) (2024/4/18) (2008/5/28) (2011/2/18) (2019/5/15) US8062837 US20220331370 PCT/US2025 US11318170 US9951309 US20220175674 (2
Slide 42: Clinical trial landscape for cell therapy
BERR ANE Re Sk aS AOE AR te 3% Dea iis Se Clinicaltrials.gov ffm PR on 33 4 (560,398 trials) Dec. 2025 update i ubepesee AAD Mpa Anaes Clinicaltrials.gov [fi Fk All G38 & on 7 AT (96,428 trials) af
Slide 43: CDMO partners and customers
MH E-Sis 2 5 (th = BR AMISAECDMO 7408270 we tis EW : chi : Pik : FDA #48 AN Re EEK GR on ed 2A Aem ch CDMO « CRO Abed awen TBMC eas & Apexcella RALBROARAS @ StemCyte RegeneCyte® = . Wi €Ereative B+ © wes wrecom nooo fl amy BSEMRR Corrigont MYCENAX AKREB KEE B ARG, T ABR, charicaviver cytsimmf tapes
Slide 44: Cord blood banking models
El All Rd A 95 - EEK THE | | | | | ] B2B B2B B2B B2C B2B B2B B2C BS MBE APIER SH Re AS) A oS I ae IbECKHS ANAS AES fe Rit Se BIR RIAA S] PS as 2 Ae fa PBMC/NK SESS 2 Aa SS MSC hae AS MSC fe B2C S53 MSC Beta tadb FS MSCH PBA (Public Bank B2B(BRAS)) #38(EPBA Access : B2C (FAL) BI 90MA TSS le FP) _«
Slide 45: Public cord blood bank and B2C channels
All RG AR 23 - 23 eS RAR IS (EEK) = 1. B2B RRERIC FA Amie) 2. B2B Shame A 3. B2C MER 93% REE ME ARR 4. B2C Ree RS hI DBR > AFI uy HALYPHHSBREMORAAMA SRS CIA ey 7 ENTE 202511818 ~ 20254128318 FSSDABRES MRA ZTE OP sOMNRRENA SORNRM ERE oR 820254 11518 (&)'s~2025% 128318 (8)ik » "i ANE 2026% 173318 61(8
Slide 46: BER
BER 4H ELAR HS - ZS AR OS ARES (BRT 8-2eae) Ooo Skins
Slide 47: Growth strategy
k#-KY = oe J StemCyte|4178 48 ASR “tutnisnnnne ee _..e ema «RTT LS A HEE ( 8072 Hi KEIE ) AS / FB / MHO0R BLA 2G Pie FDA #258 API Am RG ERA fa th fh a Be PRCDMOM AERIS USSRUR ASE 2S Hb A A AR : HARA AhE
Slide 48: @ StemCyte
@ StemCyte 4 78 TR Ae = 4 afFiel
Slide 49: Future outlook and catalysts
a fFaRel BINS : I= Hi ( (2) anaes > BLA###@ - REGENECYTE® BURA 12 OR Ais AL LRA 2 HT SS SS (2) aa API - ARG ERI) + BteMSC FDA Be} 3848 SEMI RE AE (3) ARREARS BE tie BERR ARIS fl {bts A Be \ @ StemCyte k#-KY 4178 SHR : OS - 2H Be ~ RE ~ ARIS SHAPIRO 27cthls : Roo ERR AE / ARIS AS ORAS RATE: Bet + PIR
Slide 50: kE-KY
kE-KY 4178 @ StemCyte ine 3 SIN /N=i b= RHEE
Slide 51: ESG
mkE-KY 4178 —- us d - @ StemCyte An eBRERTESE Environmental | ati 248 ‘ | Governance | Aaa! v BER SAE SIE SPER ALGEMA SHCA ML - V MRT Y ReeS Vee 3B S = 38 SK AMAR SRS FACT ZRRRRS YMRS EREERUEKIAR PRaeaS ° Re E Ss G Y 2B SMe ¥ SBS ew Nes AswWSaS ASKHSs eee AR EAR ° Y BESS ‘mse S Bit ilSWs BERSSIT Hei
Slide 52: kE-KY
kE-KY 4178 @ StemCyte + i nt
Slide 53: Summary
kE-KY HBFlz @ StemCyte|4178 x ES Bal (2 34 a aioe aS litisg is 3 he RRA iE 7k {11 - apes | | MAME ne? 2RBA ss eaemime BUSH = GTB RE FDA BLA 258 nA a Ke 5 ERS Ne JT \ JT \ J \ y |
Slide 54: Closing
kE-KY 4178 sz @ StemCyte EA Ble 7a elze BA Mee AS re eT Bl Ao eA Se B i ie 2RBBl SER Bll FDA 2 ct 4a 22 ite 2 i 3s HE A LAFDA #48 -Z ai he AP | Qe trie ARS AS AR ee a rhe Bee (ER red Be BL Bae HE FEKCDMOTHs Alie RA/RRAT/AE =m |
StemCyte International — Investor Presentation (April 2026) on 6ix